Form 8-K - Current report:
SEC Accession No. 0001213900-25-056188
Filing Date
2025-06-20
Accepted
2025-06-20 16:10:47
Documents
15
Period of Report
2025-06-17
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0246299-8k_unicycive.htm   iXBRL 8-K 35601
2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATIO ea024629901ex3-1_unicycive.htm EX-3.1 7659
3 PRESS RELEASE ISSUED ON JUNE 17, 2025 ea024629901ex99-1_unicycive.htm EX-99.1 13612
4 GRAPHIC ex99-1_001.jpg GRAPHIC 28758
  Complete submission text file 0001213900-25-056188.txt   275562

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE uncy-20250617.xsd EX-101.SCH 3017
6 XBRL LABEL FILE uncy-20250617_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE uncy-20250617_pre.xml EX-101.PRE 22360
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0246299-8k_unicycive_htm.xml XML 3903
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

EIN.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40582 | Film No.: 251061452
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)